Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “aflibercept” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 79
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 79 pipeline programs matching "aflibercept" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

79 results for “aflibercept” Back to intelligence hub

Search results

Page 2 of 4
  1. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial
  2. Prompt aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial
  3. aflibercept

    Regeneron UK Limited

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial
  4. aflibercept 8 mg PFS

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    phase 3 small molecule completed

    1 trial
  5. ARD6122

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial
  6. ARD6123

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial
  7. Aflibercept

    Regeneron UK Limited

    Radiation Retinopathy

    phase 2 small molecule active

    1 trial
  8. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial
  9. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial
  10. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial
  11. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial
  12. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Serous Chorioretinopathy

    phase 2 small molecule completed

    1 trial
  13. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Age-Related Macular Degeneration

    phase 2 small molecule completed

    2 trials
  14. Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

    Regeneron UK Limited

    Thyroid Eye Disease

    phase 2 small molecule completed

    1 trial
  15. VGFT-OD-0508

    Regeneron UK Limited

    Macular Degeneration

    phase 2 mab completed

    1 trial
  16. ZIV-Aflibercept

    Regeneron UK Limited

    Metastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial
  17. Ziv-Aflibercept

    Regeneron UK Limited

    Uveal Melanoma

    phase 2 mab terminated

    1 trial
  18. aflibercept

    Regeneron UK Limited

    Neovascular (Wet) Age-Related Macular Degeneration

    phase 2 small molecule completed

    1 trial
  19. aflibercept + FOLFIRI

    Regeneron UK Limited

    Metastatic Colorectal Cancer

    phase 2 small molecule terminated

    1 trial
  20. AVE0005 (aflibercept)

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 1 small molecule completed

    1 trial
  21. Aflibercept

    Regeneron UK Limited

    Irvine-Gass Syndrome

    phase 1 small molecule terminated

    1 trial
  22. Aflibercept

    Regeneron UK Limited

    Neovascular Macular Degeneration

    phase 1 small molecule completed

    1 trial
  23. Aflibercept (AVE0005)

    Regeneron UK Limited

    Neoplasm Malignant

    phase 1 small molecule completed

    2 trials
  24. Aflibercept every 2 months

    Regeneron UK Limited

    Radiation Retinopathy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.